BNIP3 and cancer: Importantly, consistent with our observations, recent studies have reported that mitophagy contributes to the acquisition of resistance against various anti-cancer drugs, including cisplatin and sorafenib, and demonstrated that pharmacological inhibition or genetic ablation of mitophagy components such as PINK1, BNIP3, and ATAD3 sensitizes cancer cells to chemotherapy-induced cell death [54,55,56,57].